Collegium Pharmaceutical (NASDAQ:COLL) Upgraded to “Strong-Buy” by StockNews.com

Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by equities research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report issued on Tuesday.

Several other equities research analysts have also issued reports on the stock. Piper Sandler reissued an “overweight” rating and issued a $39.00 target price (up from $37.00) on shares of Collegium Pharmaceutical in a report on Friday, February 23rd. Needham & Company LLC reaffirmed a “buy” rating and set a $40.00 price objective on shares of Collegium Pharmaceutical in a report on Thursday, April 11th. Jefferies Financial Group reaffirmed a “hold” rating and set a $37.00 price objective (up from $30.00) on shares of Collegium Pharmaceutical in a report on Thursday, January 4th. Finally, Truist Financial increased their price objective on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a report on Monday, February 26th. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $39.00.

Collegium Pharmaceutical Stock Up 3.5 %

Shares of COLL traded up $1.20 during trading hours on Tuesday, hitting $35.94. The company had a trading volume of 618,658 shares, compared to its average volume of 431,744. The firm has a fifty day moving average price of $36.97 and a 200-day moving average price of $31.11. The company has a debt-to-equity ratio of 2.48, a quick ratio of 1.10 and a current ratio of 1.17. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of 30.46 and a beta of 1.03. Collegium Pharmaceutical has a 52-week low of $20.83 and a 52-week high of $40.95.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share for the quarter, topping analysts’ consensus estimates of $1.20 by $0.25. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. The business had revenue of $149.75 million during the quarter, compared to analyst estimates of $147.66 million. On average, equities research analysts forecast that Collegium Pharmaceutical will post 5.63 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of COLL. Pacer Advisors Inc. grew its holdings in shares of Collegium Pharmaceutical by 68.4% in the fourth quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock valued at $66,938,000 after purchasing an additional 883,380 shares in the last quarter. Penn Capital Management Company LLC bought a new stake in Collegium Pharmaceutical in the fourth quarter worth $9,755,000. Assenagon Asset Management S.A. lifted its position in Collegium Pharmaceutical by 178.1% in the third quarter. Assenagon Asset Management S.A. now owns 425,630 shares of the specialty pharmaceutical company’s stock worth $9,513,000 after buying an additional 272,565 shares during the last quarter. New York State Common Retirement Fund lifted its position in Collegium Pharmaceutical by 1,475.5% in the fourth quarter. New York State Common Retirement Fund now owns 201,112 shares of the specialty pharmaceutical company’s stock worth $6,190,000 after buying an additional 188,347 shares during the last quarter. Finally, Qube Research & Technologies Ltd lifted its position in Collegium Pharmaceutical by 713.3% in the third quarter. Qube Research & Technologies Ltd now owns 127,010 shares of the specialty pharmaceutical company’s stock worth $2,839,000 after buying an additional 111,394 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.